Also today, Trius Therapeutics (TSRX) said a phase 3 trial of its tedizolid phosphate treatment for bacterial skin and skin structure infections met its primary endpoint.
FORBES: Pharma News: PDL, Trius, Alexza
应用推荐
模块上移
模块下移
不移动